Core Viewpoint - The company, 创胜集团-B (06628), announced participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where management will discuss strategic outcomes for 2026 and provide updates on ongoing business development and operational excellence plans [1] Group 1: Strategic Partnerships and Developments - The company successfully executed a strategic cooperation and non-exclusive technology licensing agreement with 台康生技股份有限公司 in December 2025, receiving upfront payments from this collaboration [1] - The company is in in-depth discussions with multiple global and regional pharmaceutical companies regarding the development and commercialization of its core assets, with several parties currently conducting due diligence or negotiating contracts [1] Group 2: Financial and Operational Efficiency - The company has implemented resource integration measures, resulting in a reduction of approximately 16% in employee numbers and a 34% decrease in labor, R&D, and other operational expenses by December 31, 2025, compared to December 31, 2024 [1] - These measures are estimated to save RMB 19 million in costs for Q4 2025 compared to Q4 2024, enhancing operational efficiency and extending the company's cash runway [1] Group 3: Liquidity and Financing Management - The company successfully negotiated repayment extensions and/or revised schedules with three suppliers for a total of approximately RMB 10 million, extending payment dates by an average of over 130 days [1] - The company has maintained good relationships with banking partners to support the renewal and extension of loan financing, having renewed bank financing of RMB 77 million and secured new financing of RMB 15 million since the last update in October 2025 [1]
创胜集团-B(06628)将出席奥本海默第36届年度医疗健康生命科学大会